Mark Cameron joins AIT Bioscience as the Vice President, Scientific Services, Ligand Binding Assays (LBA). Mark brings more than 25 years of immunoassay development and validation experience to AIT Bioscience. Mark will lead the company’s LBA programs, continuing to grow the service line in the protein bioanalysis space.
Prior to joining AIT Bioscience, Mark held positions with Beckman Coulter Diagnostics, MPI Research, Cayman Chemical and Assay Designs. He is experienced on platforms that include ELISA, MSD, Gyros and Luminex for biomarker, pharmacokinetic (PK), immunogenicity (anti-drug antibody), monoclonal antibody development screening, therapeutic antibody development screening and drug of abuse screening immunoassays.
Mark has developed, validated and or commercialized over 200 immunoassays for the diagnostic, CRO, GLP and immunoassay kit-making industries. His immunoassay products are referenced in over 1,000 publications in journals such as the Journal of Immunological Methods, Cancer Research, Bioanalysis, the AAPS Journal, and the Proceedings of the National Academy of Sciences. He is a member of the Ligand Binding Focus Group, Emerging Ligand Binding Technologies Group, the Biomarker Group and the Protein Characterization Group at AAPS. Mark has also served on the Vascular Injury Working Group) for the Predictive Safety Testing Consortium.
Mark earned a B.S. in Biology from the University of Michigan, and a M.S. in Biology from Eastern Michigan University.